Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Angelini Pharma Signs Option Agreement with Cureverse for Brain Health Asset
Details : Under the agreement, Angelini Pharma will lead all the development efforts for CV-01, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases.
Product Name : CV-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 21, 2024